Apr 2, 2008 by Brian LawlerSeattle Genetics Bulks Up Its PipelineIts biopharmaceutical clinical studies are firing on all cylinders.
Apr 2, 2008 by Brian LawlerFollowing the Drugmaker Formerly Known as NeurochemNeurochem was set to hear FDA news on its lead drug candidate Kiacta.
Apr 2, 2008 by Brian LawlerBad Timing for AstraZeneca's Good DataThe drugmaker's report on Crestor gets lost in the fuss over Vytorin.
Apr 2, 2008 by Brian LawlerAlexza Establishes a Cash PipelineThe drugmaker will have a $50 million rainy-day fund.
Apr 2, 2008 by Brian LawlerMedicines Company Sets Itself ApartA drugmaker wants to distance its angioplasty treatment from heparin.
Apr 2, 2008 by Brian LawlerA Slate of Data for ExelixisMuch of the key information will be available in May.
Apr 1, 2008 by Brian LawlerA Competitive Stab at King and PainA new, dark-horse competitor arrives to fight King Pharma and Pain Therapeutics.
Apr 1, 2008 by Brian LawlerA Little Up Front and a Lot Later for Cell GenesysCell Genesys strings in a strong partner.
Apr 1, 2008 by Brian LawlerVIVUS' New Old DrugsThe small company finds plenty of help as it tries to get its anti-obesity drug to market.
Apr 1, 2008 by Brian LawlerCephalon Plays "Let's Make a Deal"Cephalon acquires an oncology drug on the cheap.
Apr 1, 2008 by Brian LawlerThe Endo a Patent?Endo sues to protect a lead drug from generic competition.
Apr 1, 2008 by Brian LawlerBioMarin Drug Heads OverseasOne of the pharmaceutical's drugs gets approved in Japan.
Mar 31, 2008 by Brian LawlerA Little Funding for PharmassetThe company may be on to something with hepatitis C compounds.
Mar 31, 2008 by Brian LawlerSGX Down for the Count?The pharmaceutical's lead drug fares poorly in clinical testing.
Mar 31, 2008 by Brian LawlerA Good Mix for QLTQLT takes one step toward a winning combination for those who suffer from macular degeneration.
Mar 31, 2008 by Brian LawlerCorcept's Devotion to Its Lead DrugIt will try again with its compound for psychotic depression.
